Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma

Authors :: Eugene Maraskovsky
Findlay Mpn.
Jonathan Cebon
Grant A. McArthur
Bernard Mark Smithers
Peter Hersey
Ottensmeier Chh.
Jeremy Marsden
Ralph Venhaus
Michael Millward
Evans Trj.
Wendie Hopkins
Paul Nathan
Martin Gore
R Dunbar
Angus G. Dalgleish
Vincenzo Cerundolo
John F. Thompson
Ian D. Davis
Weisan Chen
Source :: Journal of Clinical Oncology. 32:9050-9050
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 9050 Background: The cancer testis antigen NY-ESO-1 (ESO) has been evaluated as a biomarker and a therapeutic immunologic cancer target. Preliminary data from a phase I clinical trial of ESO and IS...

Subjects :: Oncology
Cancer Research
Pathology
medicine.medical_specialty
business.industry
medicine.medical_treatment
Melanoma
Phases of clinical research
Cancer
medicine.disease
Internal medicine
medicine
Biomarker (medicine)
Cancer/testis antigens
Stage (cooking)
NY-ESO-1
business
Adjuvant

Full Text Access

Tools